埃克替尼治疗33例晚期非小细胞肺癌的临床分析

Clinical analysis of Icotinib in thirty-three advanced NSCLC patients

关键词:  非小细胞肺癌；靶向治疗；EGFR TKI；埃克替尼  疗效；不良反应

Key words:  [Key words]　NSCLC  targeted therapy  EGFR-TKI  icotinib  effect  adverse reaction

摘要:

目的　探讨埃克替尼治疗33例非小细胞肺癌(non small cell lung cancer,NSCLC)患者的疗效及安全性。方法　对33例患者的临床特点、治疗效果、不良反应及生存时间进行了回顾性分析。所有患者均口服埃克替尼125 mg，3次/d,直到病变进展或不能耐受。结果　KPS评分升高率为21.2%(7 例)，埃克替尼总有效率24.2%，疾病控制率87.9%。中位生存时间10.2个月,1年生存率42.4%。脑转移患者的有效率明显高于无脑转移的患者。腺癌、无脑转移、KPS评分高的患者的生存时间优于其他病理类型、有脑转移、KPS评分低的患者。埃克替尼的不良反应主要表现为轻度皮疹、皮肤干燥、腹泻。结论　埃克替尼治疗晚期NSCLC具有较好的疗效及安全性。

Abstract:

[Abstract] Objective　To evaluate the clinical efficacy and tolerability of Icotinib in advanced NSCLC patients. Methods　The clinical characteristics, response to treatment, adverse reaction and survival were retrospectively reviewed in thirty-three advanced NSCLC patients. All these patients received Icotinib 125mg three times a day until disease progression or unacceptable toxicity. Results　Seven cases (21.2%) had improved KPS score. Overall response rate and disease control rate (DCR) of Icotinib were 24.2% and 87.9%, respectively. The median survival time was 10.2 months. One year survival rate was 42.4%. The response rate to Icotinib was significantly higher in patients with brain metastasis than patients without brain metastasis. The overall survival times were significantly longer in patients of adenocarcinoma, without brain metastasis and high KPS score than patients of other pathological type, with brain metastasis and low KPS score. Rash, diarrhea and xerosis cutis were the most common adverse effects (AEs), but usually were mild. Conclusion　Icotinib has better curative effect and insignificant adverse reaction in the treatment of NSCLC.